GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » EPS (Diluted)

Sandoz Group AG (Sandoz Group AG) EPS (Diluted) : $ (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG EPS (Diluted)?

Sandoz Group AG's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.00.

Sandoz Group AG's EPS (Basic) for the three months ended in Dec. 2023 was $0.00.

Sandoz Group AG's EPS without NRI for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Sandoz Group AG EPS (Diluted) Historical Data

The historical data trend for Sandoz Group AG's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG EPS (Diluted) Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
EPS (Diluted)
1.97 0.18

Sandoz Group AG Quarterly Data
Dec22 Dec23
EPS (Diluted) - -

Competitive Comparison of Sandoz Group AG's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandoz Group AG's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's PE Ratio falls into.



Sandoz Group AG EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Sandoz Group AG's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(77-0)/431.200
=0.18

Sandoz Group AG's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(77-0)/431.200
=0.18


Sandoz Group AG  (OTCPK:SDZNY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sandoz Group AG EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG (Sandoz Group AG) Business Description

Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024